MOTS-c — Safety, Research, Risks & Legal Status

Not medical advice. MOTS-c is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	mitochondrial open reading frame of the twelve S rRNA-c, mitochondrial-derived peptide
Category	Peptide
not_fda_approved	Research chemical; no human clinical trials completed
mitochondrial_encoded	Derived from non-coding mitochondrial DNA sequence; represents emerging class of mitokines
preclinical_mostly	Evidence base is almost entirely animal and cell-culture research
US legal status	MOTS-c is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has no approved medical indication. Mitochondrial-derived peptides and their analogs may fall under WADA's prohibited categories, so athletes should treat it as a doping risk.

What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA that appears to act as a signaling molecule influencing metabolism. Unlike the GH secretagogues, it is studied for effects on insulin sensitivity and metabolic regulation rather than growth hormone release. MOTS-c represents a distinct class of bioactive peptides generated from non-coding mitochondrial sequences.

How it works

MOTS-c is a 16-amino-acid peptide derived from the D-loop region of mitochondrial DNA. It acts as a circulating signaling molecule, likely activating cellular or tissue receptors to modulate metabolic pathways. Research suggests it activates AMPK (AMP-activated protein kinase) and related metabolic sensors, leading to improvements in glucose utilization and insulin sensitivity. The exact receptor and signaling cascade remain incompletely defined.

Background & history

MOTS-c was discovered and characterized in 2015 by researchers investigating bioactive peptides encoded in non-coding regions of mitochondrial DNA. It represents an emerging class of 'mitokines' or mitochondrial-derived peptides that regulate systemic metabolism. Research is still in early stages, with most studies conducted in cell cultures and rodent models rather than humans.

What the research says

Research is largely preclinical: animal and cell studies suggest MOTS-c can improve insulin sensitivity, influence glucose and lipid metabolism, and activate AMPK-related pathways, with some studies reporting exercise-mimetic effects in mice. Human clinical evidence is very limited and early, so claims should be viewed as preliminary. No controlled human trials of MOTS-c exist to date.

Reported effects

Reported improvements in insulin sensitivity in animal studies
Studied effects on glucose and lipid metabolism
Reported exercise-mimetic and metabolic effects in mice
Studied activation of AMPK-related metabolic pathways
Reported effects on mitochondrial function in cell studies
Studied potential anti-inflammatory signaling

Dosing & administration (informational)

In animal models, MOTS-c has been administered intravenously or intraperitoneally in doses ranging from nanomoles to micromoles per kilogram, with metabolic effects observed over hours to days. No human clinical dosing data exist, and no approved protocols for human use have been established.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Injection carries risks of pain, bruising, infection, and injection-site reactions without sterile technique
Human safety data are very limited, so long-term and systemic risks are not well characterized
Effects on glucose handling are theoretical in humans and could alter blood sugar control
Athletes should treat metabolic-modulating peptides as a potential WADA doping risk
Sold as a research chemical with no quality assurance, so contamination and mislabeling are real concerns
Long-term effects on mitochondrial function and cellular energetics are unknown in humans

Drug & supplement interactions

AMPK inhibitors may antagonize MOTS-c effects
Metformin and other AMPK activators may have additive or overlapping effects (not studied together)
Interaction with insulin and glucose-regulating drugs not characterized in humans
Effects with exercise not well-studied in humans

Who should avoid it

Insulin-dependent diabetes (glucose-lowering effects could pose hypoglycemia risk)
Severe mitochondrial disease or myopathy
Acute metabolic derangement or crisis
Pregnancy (unknown effects)
Athletes competing in WADA-regulated sports

How it is commonly combined

MOTS-c is not typically combined with other peptides or drugs in human studies, as it is not approved for human use and interactions are not characterized. Concurrent use with other metabolic modulators is not recommended and may pose unpredictable risks.

Legal & regulatory. MOTS-c is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has no approved medical indication. Mitochondrial-derived peptides and their analogs may fall under WADA's prohibited categories, so athletes should treat it as a doping risk.

Quality & harm reduction

R
e
q
u
i
r
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
f
o
r
a
n
y
p
r
o
d
u
c
t
.
L
o
o
k
f
o
r
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
d
a
t
a
.
E
n
d
o
t
o
x
i
n
(
L
A
L
)
t
e
s
t
i
n
g
i
s
i
m
p
o
r
t
a
n
t
f
o
r
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
s
.
U
s
e
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
a
n
d
c
o
l
d
s
t
o
r
a
g
e
t
o
p
r
e
s
e
r
v
e
s
t
a
b
i
l
i
t
y
a
n
d
p
r
e
v
e
n
t
m
i
c
r
o
b
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is MOTS-c a growth hormone peptide?

No. Unlike the GH secretagogues, MOTS-c is a mitochondrial-derived peptide studied mainly for metabolic and insulin-sensitivity effects.

Is there human evidence for MOTS-c?

Most evidence is from animal and cell studies. Human clinical data are very limited and early, so benefits remain unproven.

What is the right dose?

We do not provide human dosing guidance for unapproved research chemicals.

How does MOTS-c differ from GH peptides?

MOTS-c does not stimulate growth hormone; instead, it is studied for metabolic regulation, insulin sensitivity, and AMPK activation via distinct signaling pathways.

Is MOTS-c banned in sport?

WADA does not have a specific category for mitochondrial-derived peptides, but novel peptides may face scrutiny; athletes should treat it as a potential doping risk.

References & further reading

PubMed: MOTS-c mitochondrial-derived peptide
PubMed: MOTS-c insulin sensitivity AMPK
PubMed: mitochondrial-derived peptides metabolism
WADA: novel peptides doping
ClinicalTrials.gov: mitochondrial peptide metabolic health